

- abnobaVISCUM, Helixor, Iscador and Iscucin (status May 2020)" (accessed Apr. 26, 2021).
11. A. Ladanie, et al. "Clinical trial evidence supporting US Food and Drug Administration approval of novel cancer therapies between 2000 and 2016," *Op. cit.*
 12. P. Sharma, et al. "Primary, adaptive, and acquired resistance to cancer immunotherapy," *Cell*, 168, Feb. 9, 2017 a 2017 Elsevier Inc. 168(4): 707–23 (2017).
 13. "Cancer: Key Statistics," World Health Organization. <https://www.who.int/cancer/resources/keyfacts/en/>. Retrieved Apr. 30, 2021.
 14. A. S. Blevins Primeau, "Cancer recurrence statistics," *Cancer Therapy Adviser Factsheet*, Nov. 30, 2018, at: <https://www.cancertherapyadviser.com/home/tools/fact-sheets/cancer-recurrence-statistics/>. Retrieved Apr. 30, 2021.
 15. "Right to Try," *FDA Fact Sheet*, updated Jan. 14, 2020; <https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try> (retrieved Apr. 30, 2021).

APPENDIX B

1. S. C. Howard, et al. "The tumor lysis syndrome," *The New England Journal of Medicine*, vol. 364,19 (2011): 1844–54. doi:10.1056/NEJMra0904569.

APPENDIX D

1. S. Sen, et al. "Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase-1 clinical trials," *British Journal of Cancer*, vol. 118,6 (2018): 763–69. doi:10.1038/bjc.2017.480.